Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens

Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu Yun Leu, Gajanan Bhat, Adam Brufsky

Producción científica: Articlerevisión exhaustiva


Purpose: Poziotinib is an irreversible pan-inhibitor of the human epidermal growth factor receptor (HER) that has shown acceptable tolerability and antitumor activity in phase I and II trials in patients with advanced solid tumors. In the present open-label, multicenter phase II study, we demonstrate safety, tolerability, and preliminary efficacy data from two different dosing schedules in patients with HER2-positive advanced breast cancer. Patients and methods: Patients who had received at least two prior HER2-directed therapy lines for advanced disease, received 24 mg poziotinib on an intermittent dosing schedule (cohort 1) or 16 mg poziotinib once daily on a continuous dosing schedule (cohort 2). The primary endpoint was overall response rate (ORR). Secondary endpoints were progression-free survival (PFS), disease control rate (DCR), and time to progression (TTP). Secondary endpoints additionally included safety and pharmacokinetics. Results: A total of 67 patients were enrolled. The ORR was 30% in both groups (p = 0.98). DCR was 60% vs 78% (p = 0.15) and median PFS and TTP were 4.1 vs 4.9 months (both p = 0.30) for cohorts 1 and 2, respectively. The most common treatment related adverse events (AEs) of any grade included diarrhea (88% vs 85%, p = 0.76), rash (88% vs 88%, p = 0.96), and stomatitis (64% vs 56%, p = 0.52), with grade 3–4 diarrhea occurring in 33% vs 32% of patients (p = 0.93) and grade 3–4 rash in 27% vs 35% of patients (p = 0.48) in cohort 1 vs cohort 2, respectively. Conclusion: Poziotinib demonstrated evidence of clinical activity in patients with pre-treated HER2-positive advanced breast cancer, although high levels of toxicity may preclude further studies at this time.

Idioma originalEnglish (US)
Páginas (desde-hasta)29-37
Número de páginas9
PublicaciónBreast Cancer Research and Treatment
EstadoPublished - may 2024

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Profundice en los temas de investigación de 'Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens'. En conjunto forman una huella única.

Citar esto